ARQ 197 (tivantinib)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for ARQ 197 (tivantinib), covering 2013-02-25 to 2017-10-09. Get the full timeline:
Most recent: Clinical Trial Update: A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) [Phase 3]